News
Will upstream raw material companies be affected as the 2025 IVD centralized procurement expands to molecular diagnostics

Will upstream raw material companies be affected as the 2025 IVD centralized procurement expands to molecular diagnostics

Under the continuous influence of industry policy dynamics, the scope of centralized procurement in the field of in vitro diagnostics (IVD) will be further expanded to include molecular diagnostics by 2025. This measure has attracted widespread attention from both upstream and downstream of the industrial chain, especially upstream raw material enterprises, whose development trend under the new policy framework has attracted much attention. Molecular diagnostics, as a high-tech and rapidly developing sub field in the IVD industry, will have a profound impact on upstream raw material enterprises from multiple dimensions through the expansion of centralized procurement.

2025-10-15

MORE +
Three key actions to accelerate the IVD raw material supply chain from a 3-month delivery period to a 3-week delivery period

Three key actions to accelerate the IVD raw material supply chain from a 3-month delivery period to a 3-week delivery period

By implementing demand forecasting, optimizing supplier networks, and implementing lean production management, the IVD raw material supply chain can significantly improve operational efficiency, seize opportunities in fierce market competition, and provide solid guarantees for the rapid development of the IVD industry.

2025-10-14

MORE +
The survival of small and medium-sized enterprises in IVD: finding a way to break through in the cold winter

The survival of small and medium-sized enterprises in IVD: finding a way to break through in the cold winter

The current competition in the IVD industry is intensifying, market concentration is increasing, and small and medium-sized enterprises are facing enormous pressure. The key to breaking through lies in three strategies: focusing on high threshold and high potential niche areas, and creating differentiated advantages; Actively expanding overseas emerging markets and seeking incremental space; Strengthen collaborative cooperation in the industrial chain, enhance risk resistance through resource integration and cost optimization. Only innovation and focus can achieve sustainable development in fierce competition.

2025-10-13

MORE +
What is the key to the over 50% market share of domestically produced chemiluminescence?

What is the key to the over 50% market share of domestically produced chemiluminescence?

As a core technology for in vitro diagnostics, chemiluminescence has made significant progress in localization in recent years, with a market share exceeding 50%. This achievement is due to technological breakthroughs breaking the import monopoly, accelerated substitution of centralized procurement policies, product cost-effectiveness advantages, and coordinated improvement of the industrial chain. Taking Xindesheng as an example, the company focuses on the research and production of key raw materials such as acridine ester and luminol. The products have high luminescence efficiency and good batch consistency, providing important support for improving the performance of domestic chemiluminescence reagents.

2025-10-12

MORE +
From Cell Culture to Diagnostic Detection: Multi Domain Application Scenarios Analysis of PIPES Buffer Solution

From Cell Culture to Diagnostic Detection: Multi Domain Application Scenarios Analysis of PIPES Buffer Solution

PIPES buffer has become a trusted choice for many researchers and enterprises due to its excellent chemical stability and wide applicability. This article will take you to a deeper understanding of the practical applications of PIPES buffer in multiple key fields, exploring how it plays a critical role in different scenarios.

2025-10-09

MORE +
The rise of domestic IVD raw materials: New Desheng Biological Buffer from "usable" to "easy to use"

The rise of domestic IVD raw materials: New Desheng Biological Buffer from "usable" to "easy to use"

Hubei Xindesheng has achieved high purity (≥ 99%) and batch stability of biological buffering agents (such as Tris, HEPES, etc.) through continuous technological innovation and strict quality control, breaking through the dilemma of domestic raw materials being difficult to use. The company has the ability to produce on a large scale and provides customized services, effectively meeting the stringent requirements of the IVD industry in terms of sensitivity, repeatability, and stability, and helping to improve the performance of domestic detection reagents.

2025-10-04

MORE +
< 1...101112...50 >